Robert B Eisenberg, MD
Urology · Chula Vista
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 7
- Since medical school
- 54 years
- Graduated 1972
Offices
7 locations · United Urology Consultants, P.C. · First Choice Physician Partners · Emergency and Acute Care Medical Corporation · County of Santa Clara · Kaweah Delta Health Care District
Looking this up.
Hospitals listed: Doctors Medical Center · Emanuel Medical Center · Kaweah Health Medical Center · Memorial Medical Center. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Eisenberg’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A31900 · Current
Licensed to practise in California · since 1978 · expires 2028-10-31 · Autonomous University of Guadalajara Faculty of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
4 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Doctors Medical CenterModesto, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of Tenet Healthcare, which runs 77 hospitals in 12 statesPatients rate it 2 of 5 · 59% would definitely recommend itOverall rating: 1 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.36 (1.02 to 1.71), Jul 2022 – Jun 2024Worse than the national rate — Pressure ulcer rate: 1.35 (0.81 to 1.9) · 6,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.281, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.326, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.183, Oct 2024 – Sep 2025
- Emanuel Medical CenterTurlock, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of Tenet Healthcare, which runs 77 hospitals in 12 statesPatients rate it 2 of 5 · 58% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.231, Oct 2024 – Sep 2025
- Kaweah Health Medical CenterVisalia, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of Kaweah Delta Health Care DistrictPatients rate it 3 of 5 · 67% would definitely recommend itOverall rating: 3 of 5 starsWorse than the national rate — Death rate among surgical inpatients with serious treatable complications: 239.86 (194.11 to 285.6) · 104 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025
- Memorial Medical CenterModesto, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 72% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.093, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.085, Oct 2024 – Sep 2025
See every measure and the patient survey for Doctors Medical Center
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 2 better, 3 the same, 1 worse of 6 measures. Readmissions: 0 better, 5 the same, 3 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.36 (1.02 to 1.71) | Worse | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.35 (0.81 to 1.9) · 6,296 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.281 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.326 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.183 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.27 (0.31 to 2.23) · 1,396 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 183.31 (147.26 to 219.36) · 127 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 4.1 · 135 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.1 · 95 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 15.2 · 276 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12.8 · 321 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.2 · 364 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.9 · 767 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.6 · 3,719 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.37) · 7,050 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.05 to 0.43) · 7,169 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.12 (2.19 to 6.06) · 1,622 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.6 (0 to 3.3) · 48 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.63 (1.23 to 4.04) · 1,601 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 14.79 (5.73 to 23.85) · 51 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.99 (0.75 to 9.23) · 51 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.65 (0.17 to 3.13) · 242 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.9 · 67 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.484 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.582 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.3 · 424 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24 · 682 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 36.6 · 326 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 70.5 · 378 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 366 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.2 · 564 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 70 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 14.7 · 120 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.1 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.4 to 16.4) · 573 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.3 (1 to 1.7) · 303 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,045 patients answered, 15% of those asked)
| Cleanliness | 2 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 2 |
| Room was "always" clean | 63% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 67% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 57% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 36% |
| "YES", patients would definitely recommend the hospital | 59% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Emanuel Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 7 the same, 3 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.231 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.92 (0 to 1.94) · 622 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.46 to 1.27) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 185.82 (131.99 to 239.65) · 55 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 10.8 · 72 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.9 · 287 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12 · 365 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.9 · 443 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.3 · 102 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.2 · 1,680 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.39) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.03 to 0.44) · 4,151 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.53 (1.2 to 5.87) · 700 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.84 (1.24 to 4.43) · 734 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.7 (0.19 to 3.2) · 146 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 1.04) · 3,326 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.2 · 45 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.908 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.836 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.997 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.2 · 307 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.2 · 461 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -12.8 · 290 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -3.8 · 417 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 37.9 · 472 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 20.1 · 524 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (3.9 to 7.6) · 264 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.7 (7.4 to 12.8) · 264 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 40 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.6 · 111 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.2 (10.5 to 19.3) · 257 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.6 to 1.2) · 289 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 14% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 2 |
| Room was "always" clean | 74% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 73% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 79% |
| Doctors "always" explained things so they could understand | 67% |
| Doctors "always" listened carefully | 71% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 60% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 39% |
| "YES", patients would definitely recommend the hospital | 58% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Kaweah Health Medical Center
Behind the star rating — Deaths: 0 better, 5 the same, 3 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 239.86 (194.11 to 285.6) · 104 cases | Worse | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.22 (0.28 to 2.16) · 1,600 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.53 to 1.09) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.4 · 145 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 9.7 · 226 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.3 · 285 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 14.8 · 626 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 18.1 · 741 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.7 · 373 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.6 · 3,927 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.27 (0.08 to 0.46) · 9,045 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.19 (0.01 to 0.38) · 9,267 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.72 (1.81 to 5.63) · 2,251 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.07 (0.53 to 3.61) · 768 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.79 (0.45 to 3.13) · 2,231 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.88 (1.1 to 12.66) · 799 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 3.59 (0 to 7.19) · 759 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 416 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.35 (0 to 0.89) · 8,159 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 43 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.728 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.405 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.023 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.551 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.9 · 344 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.2 · 799 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -17 · 286 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 31.4 · 686 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -6 · 734 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.4 · 776 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.3 (3.6 to 7.6) · 202 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 8.9 (6.6 to 11.9) · 202 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 32 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.6 · 142 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 317 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 10.8 (8.3 to 14) · 1,748 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 680 cases | No different | Jan 2024 – Dec 2024 |
What patients said (435 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 68% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 48% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Memorial Medical Center
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 9 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.093 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.085 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.3 (0.41 to 2.2) · 2,271 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.75 to 1.3) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 185.77 (144.66 to 226.88) · 146 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.2 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.2 · 237 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 14.1 · 194 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12.9 · 513 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.4 · 640 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 278 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.5 · 4,882 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.03 to 0.42) · 10,183 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 10,422 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.4 (1.58 to 5.23) · 2,596 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.92 (0.45 to 3.38) · 845 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 3.1 (1.78 to 4.42) · 2,439 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.71 (5.69 to 17.72) · 885 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.28 (3.75 to 10.81) · 829 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.82 (0.4 to 3.24) · 563 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.2 (0 to 0.72) · 9,080 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 283 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.389 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.485 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.507 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15 · 255 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.9 · 849 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 19.2 · 201 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -8.4 · 584 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 26.6 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.9 · 895 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.8 (3.3 to 6.9) · 285 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11 (8.4 to 14.3) · 285 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.9 · 273 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.7 · 108 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.4 · 341 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.9 (10.2 to 16.1) · 2,334 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 717 cases | No different | Jan 2024 – Dec 2024 |
What patients said (655 patients answered, 19% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 72% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 74% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 44% |
| "YES", patients would definitely recommend the hospital | 72% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$67,735
Medicare paid this office $67,735 for 267 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 110 | $9,906 | $65 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 70 | $7,524 | $102 |
| Diagnostic exam of bladder and urethra using an endoscope | 26 | $5,988 | $187 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 14 | $4,489 | $321 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 31 | $2,736 | $62 |
See all 10 services
| Short return visit (20+ min) | 110 | $9,906 | $65 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 70 | $7,524 | $102 |
| Diagnostic exam of bladder and urethra using an endoscope | 26 | $5,988 | $187 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 14 | $4,489 | $321 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 31 | $2,736 | $62 |
| Return visit (30+ min) | 20 | $2,596 | $100 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 39 | $2,285 | $38 |
| Insertion of stent in ureter using an endoscope | 15 | $1,636 | $102 |
| Simple insertion of temporary bladder tube | 11 | $924 | $51 |
| Automated urinalysis test | 118 | $427 | $2 |
Procedures Medicare counted
| Prostate resection | 1-10 | None |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Diagnostic exam of bladder and urethra using an endoscope | 63 | 58 | 55 | 61 | 41 | 32 |
| Simple insertion of temporary bladder tube | 41 | 31 | 21 | 45 | 65 | 18 |
| Ultrasound measurement of bladder capacity after voiding | 43 | 61 | 50 | 42 | 16 | – |
| Insertion of stent in ureter using an endoscope | 18 | 17 | 20 | 12 | 15 | 16 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 13 | – | 16 | – | – | – |
| Crushing of stone of ureter with insertion of stent using an endoscope | – | – | – | 11 | – | 14 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
267 Original Medicare patients in 2024. Average age 74 · Under 65 12% · 85 and older 17% · Women 27% · Also on Medicaid 42% · Health risk score 1.82. Above the middle of the specialty; the typical urology clinician is at 1.36.
Conditions among them: High blood pressure 75% · Diabetes 48% · Chronic kidney disease 48% · Coronary heart disease 37% · Cancer 28% · Heart failure 27% · Atrial fibrillation 27% · Depression 26% · COPD 18% · Stroke 16% · Dementia 12%.
The office billed $253,423, Medicare allowed $88,412 and paid $67,735; for 1,305 services of 57 kinds; $4,919 of it was for drugs given in the office and $62,816 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 267 | 1,305 | 74 | 1.82 | $253,423 | $67,735 |
| 2023 | 349 | 1,621 | 76 | 1.71 | $290,661 | $77,903 |
| 2022 | 389 | 2,454 | 75 | 1.57 | $359,559 | $105,824 |
| 2021 | 385 | 2,363 | 74 | 1.72 | $366,021 | $109,428 |
| 2020 | 404 | 5,546 | 74 | 1.81 | $469,423 | $133,849 |
| 2019 | 520 | 9,766 | 74 | 1.93 | $503,168 | $139,078 |
| 2018 | 482 | 5,120 | 74 | 1.79 | $465,608 | $125,665 |
| 2017 | 582 | 5,430 | 75 | 1.70 | $479,080 | $125,923 |
| 2016 | 919 | 7,892 | 74 | 1.79 | $803,111 | $229,652 |
| 2015 | 666 | 5,635 | 74 | 1.69 | $665,913 | $184,023 |
| 2014 | 488 | 2,214 | 73 | 1.83 | $549,733 | $153,450 |
| 2013 | 521 | 2,235 | 74 | 1.98 | $654,239 | $171,249 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 14 services
| Short return visit (20+ min) | 162 | $14,772 | $65 |
| Diagnostic exam of bladder and urethra using an endoscope | 35 | $7,906 | $193 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 67 | $6,815 | $102 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 12 | $5,697 | None |
| Return visit (30+ min) | 32 | $4,049 | $101 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 36 | $3,553 | $63 |
| Simple insertion of temporary bladder tube | 29 | $3,122 | $48 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $1,801 | $129 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 30 | $1,638 | $39 |
| Insertion of stent in ureter using an endoscope | 13 | $1,489 | $99 |
| New patient visit (30+ min) | 14 | $845 | $60 |
| Automated urinalysis test | 139 | $414 | $2 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $398 | $25 |
| Ultrasound measurement of bladder capacity after voiding | 13 | $127 | $8 |
2022: 16 services
| Short return visit (20+ min) | 201 | $19,750 | $64 |
| Diagnostic exam of bladder and urethra using an endoscope | 50 | $11,498 | $188 |
| Return visit (30+ min) | 59 | $7,653 | $97 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 12 | $6,374 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 50 | $4,188 | $57 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 51 | $4,089 | $79 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 11 | $3,530 | $321 |
| Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | 13 | $3,456 | $266 |
| Simple insertion of temporary bladder tube | 28 | $2,197 | $49 |
| New patient visit (30+ min) | 22 | $1,678 | $76 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 34 | $1,399 | $31 |
| Insertion of stent in ureter using an endoscope | 12 | $968 | $81 |
| Automated urinalysis test | 202 | $738 | $2 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $395 | $25 |
| Ultrasound measurement of bladder capacity after voiding | 33 | $314 | $7 |
| Imaging of urinary tract following injection of a contrast agent | 12 | $248 | $21 |
2021: 17 services
| Short return visit (20+ min) | 173 | $17,366 | $64 |
| Diagnostic exam of bladder and urethra using an endoscope | 38 | $10,144 | $184 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 16 | $9,521 | $595 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 14 | $9,204 | None |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 69 | $5,958 | $83 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 57 | $4,958 | $59 |
| Return visit (30+ min) | 40 | $4,855 | $99 |
| Insertion of stent in ureter using an endoscope | 19 | $2,285 | $114 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 19 | $2,124 | $112 |
| New patient visit (30+ min) | 23 | $2,102 | $91 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 46 | $1,903 | $31 |
| Destruction of tissue of bladder, urethra, or surrounding glands using an endoscope | 11 | $1,369 | $124 |
| Simple insertion of temporary bladder tube | 12 | $1,150 | $55 |
| Automated urinalysis test | 181 | $704 | $2 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 13 | $475 | $24 |
| Imaging of urinary tract following injection of a contrast agent | 20 | $439 | $21 |
| Ultrasound measurement of bladder capacity after voiding | 39 | $397 | $8 |
2020: 19 services
| Short return visit (20+ min) | 194 | $14,559 | $52 |
| Diagnostic exam of bladder and urethra using an endoscope | 44 | $9,507 | $164 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 12 | $8,506 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 52 | $4,918 | $60 |
| Return visit (30+ min) | 47 | $4,112 | $71 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 34 | $3,902 | $108 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 41 | $3,440 | $84 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 51 | $2,414 | $32 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,275 | $152 |
| Insertion of stent in ureter using an endoscope | 16 | $1,927 | $113 |
| Destruction of tissue of bladder, urethra, or surrounding glands using an endoscope | 13 | $1,716 | $132 |
| Simple insertion of temporary bladder tube | 19 | $1,631 | $53 |
| New patient visit (30+ min) | 21 | $1,537 | $73 |
| Telephone medical discussion with physician, 11-20 minutes | 13 | $782 | $60 |
| Automated urinalysis test | 182 | $649 | $2 |
| Ultrasound measurement of bladder capacity after voiding | 44 | $480 | $8 |
| Imaging of urinary tract following injection of a contrast agent | 17 | $452 | $22 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $304 | $22 |
| Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic | 12 | $113 | $9 |
2019: 20 services
| Short return visit (20+ min) | 237 | $17,914 | $50 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 19 | $14,906 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 57 | $8,702 | $138 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 92 | $8,068 | $58 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 13 | $7,703 | $593 |
| Return visit (30+ min) | 68 | $6,960 | $80 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 71 | $5,859 | $80 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 63 | $3,097 | $32 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 20 | $2,330 | $111 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,140 | $165 |
| Simple insertion of temporary bladder tube | 23 | $2,077 | $51 |
| Insertion of stent in ureter using an endoscope | 17 | $1,690 | $94 |
| New patient visit (30+ min) | 20 | $1,414 | $71 |
| Simple change of bladder tube | 14 | $1,384 | $73 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 19 | $701 | $26 |
| Imaging of urinary tract following injection of a contrast agent | 25 | $551 | $21 |
| Injection of drug or substance under skin or into muscle | 16 | $485 | $12 |
| Ultrasound measurement of bladder capacity after voiding | 37 | $431 | $10 |
| Automated urinalysis test | 118 | $376 | $2 |
| Injection, testosterone cypionate, 1 mg | 14 | $139 | None |
2018: 21 services
| Short return visit (20+ min) | 213 | $17,427 | $51 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 19 | $11,118 | $585 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 87 | $8,534 | $58 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 12 | $8,177 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 57 | $8,043 | $115 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 48 | $5,258 | $110 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 14 | $4,748 | $339 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 25 | $4,251 | $163 |
| Return visit (30+ min) | 44 | $3,585 | $80 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 30 | $2,388 | $80 |
| New patient visit (30+ min) | 33 | $1,964 | $60 |
| Simple change of bladder tube | 15 | $1,952 | $72 |
| Insertion of stent in ureter using an endoscope | 19 | $1,881 | $86 |
| Simple insertion of temporary bladder tube | 16 | $1,281 | $46 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 19 | $843 | $31 |
| Ultrasound measurement of bladder capacity after voiding | 49 | $811 | $12 |
| Automated urinalysis test | 172 | $729 | $3 |
| Imaging of urinary tract following injection of a contrast agent | 29 | $458 | $14 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $381 | $22 |
| Injection of drug or substance under skin or into muscle | 11 | $236 | $17 |
| Manual urinalysis test with examination using microscope, automated | 16 | $65 | $4 |
2017: 22 services
| Short return visit (20+ min) | 300 | $21,978 | $49 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 16 | $13,175 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 81 | $11,727 | $117 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 12 | $7,966 | $664 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 70 | $7,338 | $56 |
| New patient visit (30+ min) | 51 | $3,660 | $72 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $3,520 | $153 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 30 | $3,271 | $109 |
| Return visit (30+ min) | 34 | $2,705 | $71 |
| Simple insertion of temporary bladder tube | 31 | $2,038 | $47 |
| Simple change of bladder tube | 14 | $1,801 | $62 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 23 | $1,795 | $78 |
| Insertion of stent in ureter using an endoscope | 15 | $1,071 | $71 |
| Ultrasound measurement of bladder capacity after voiding | 56 | $964 | $14 |
| Automated urinalysis test | 191 | $803 | $3 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 17 | $661 | $23 |
| Short return visit | 21 | $643 | $27 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 15 | $636 | $30 |
| Injection of drug or substance under skin or into muscle | 13 | $392 | $19 |
| Urinalysis, manual test | 73 | $264 | $3 |
| Imaging of urinary tract following injection of a contrast agent | 16 | $226 | $14 |
| Manual urinalysis test with examination using microscope, automated | 35 | $175 | $4 |
2016: 27 services
| Short return visit (20+ min) | 588 | $47,975 | $53 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 30 | $29,178 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 132 | $22,576 | $156 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 17 | $11,652 | $685 |
| New patient visit (30+ min) | 107 | $8,522 | $79 |
| Return visit (30+ min) | 85 | $7,774 | $83 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 59 | $6,143 | $53 |
| Simple change of bladder tube | 26 | $5,099 | $72 |
| New patient visit (45+ min) | 35 | $4,129 | $118 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $3,934 | $164 |
| Ultrasound measurement of bladder capacity after voiding | 181 | $3,585 | $15 |
| Biopsy of prostate gland | 16 | $2,666 | $167 |
| Simple insertion of temporary bladder tube | 29 | $2,339 | $53 |
| Urinalysis, manual test | 393 | $2,220 | $3 |
| Simple bladder irrigation and/or instillation | 27 | $2,104 | $66 |
| Ultrasound scan of pelvic region through rectum | 20 | $1,577 | $79 |
| Insertion of stent in ureter using an endoscope | 16 | $1,405 | $88 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 31 | $1,238 | $26 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 16 | $1,199 | $75 |
| Injection of drug or substance under skin or into muscle | 32 | $818 | $21 |
| Ultrasonic guidance for needle placement | 16 | $803 | $50 |
| Short return visit | 24 | $782 | $33 |
| Automated urinalysis test | 133 | $537 | $3 |
| Electronic assessment of bladder emptying | 33 | $327 | $8 |
| Manual urinalysis test with examination using microscope, automated | 59 | $300 | $4 |
| Manual urinalysis test with examination using microscope, non-automated | 34 | $173 | $4 |
| Injection, garamycin, gentamicin, up to 80 mg | 20 | $22 | None |
2015: 26 services
| Short return visit (20+ min) | 367 | $28,161 | $57 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 21 | $22,534 | None |
| Return visit (30+ min) | 201 | $19,474 | $74 |
| Diagnostic exam of bladder and urethra using an endoscope | 95 | $16,562 | $161 |
| New patient visit (45+ min) | 80 | $9,792 | $122 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 11 | $7,253 | $659 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 49 | $6,354 | $59 |
| New patient visit (30+ min) | 68 | $5,487 | $81 |
| Simple change of bladder tube | 16 | $4,834 | $72 |
| Biopsy of prostate gland | 22 | $4,077 | $170 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $3,954 | $165 |
| Urinalysis, manual test | 372 | $2,254 | $3 |
| Ultrasound measurement of bladder capacity after voiding | 113 | $2,082 | $15 |
| Ultrasound scan of pelvic region through rectum | 23 | $1,974 | $79 |
| Simple insertion of temporary bladder tube | 16 | $1,529 | $59 |
| Insertion of stent in ureter using an endoscope | 14 | $1,302 | $87 |
| Diagnostic exam of bladder and urethra using an endoscope | 14 | $1,195 | $80 |
| Aspiration of bladder with insertion of bladder tube to skin | 11 | $1,135 | $103 |
| Ultrasonic guidance for needle placement | 20 | $1,103 | $50 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 22 | $874 | $25 |
| Injection of drug or substance under skin or into muscle | 27 | $722 | $21 |
| Short return visit | 15 | $544 | $34 |
| Electronic assessment of bladder emptying | 16 | $158 | $10 |
| Manual urinalysis test with examination using microscope, non-automated | 18 | $80 | $4 |
| Automated urinalysis test | 21 | $66 | $3 |
| Injection, garamycin, gentamicin, up to 80 mg | 23 | $27 | None |
2014: 17 services
| Return visit (30+ min) | 300 | $40,033 | $79 |
| Diagnostic exam of bladder and urethra using an endoscope | 96 | $16,138 | $154 |
| New patient visit (45+ min) | 87 | $10,551 | $121 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 45 | $7,356 | $163 |
| Short return visit (20+ min) | 105 | $6,995 | $52 |
| Simple change of bladder tube | 14 | $5,370 | $71 |
| Biopsy of prostate gland | 19 | $3,193 | $160 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $2,516 | $84 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 31 | $2,510 | $57 |
| Urinalysis, manual test | 349 | $2,244 | $3 |
| New patient visit (30+ min) | 27 | $2,021 | $75 |
| Ultrasound scan of pelvic region through rectum | 20 | $1,637 | $74 |
| Ultrasound measurement of bladder capacity after voiding | 67 | $1,344 | $16 |
| Ultrasonic guidance for needle placement | 19 | $1,225 | $61 |
| Injection of drug or substance under skin or into muscle | 18 | $376 | $20 |
| Electronic assessment of bladder emptying | 22 | $167 | $8 |
| Injection, garamycin, gentamicin, up to 80 mg | 16 | $17 | None |
2013: 22 services
| Return visit (30+ min) | 294 | $38,960 | $79 |
| Diagnostic exam of bladder and urethra using an endoscope | 96 | $18,551 | $160 |
| New patient visit (45+ min) | 129 | $15,558 | $121 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 11 | $14,594 | None |
| Short return visit (20+ min) | 144 | $12,201 | $55 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 15 | $9,964 | $664 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 53 | $5,721 | $108 |
| Simple change of bladder tube | 15 | $5,174 | $70 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 36 | $2,843 | $79 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 26 | $2,548 | $57 |
| Ultrasonic guidance for needle placement | 12 | $2,294 | $176 |
| Biopsy of prostate gland | 12 | $2,275 | $175 |
| New patient visit (30+ min) | 22 | $1,933 | $88 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,751 | $159 |
| Urinalysis, manual test | 240 | $1,475 | $3 |
| Insertion of stent in ureter using an endoscope | 12 | $1,248 | $96 |
| Ultrasound measurement of bladder capacity after voiding | 41 | $820 | $17 |
| Ultrasound scan of pelvic region through rectum | 12 | $792 | $61 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $494 | $21 |
| Injection of drug or substance under skin or into muscle | 11 | $325 | $22 |
| Electronic assessment of bladder emptying | 16 | $147 | $8 |
| Insertion of needle into vein for collection of blood sample | 11 | $41 | $3 |
Medicaid work
$3,368 in 2024
Medicaid paid $3,368 for 311 billed services this clinician did in 2024, up to 28 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 123 | $3,106 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy | 188 | $262 |
| 2024 | 311 | 2 | 28 | $3,368 |
| 2023 | 261 | 3 | 32 | $3,654 |
| 2022 | 326 | 2 | 31 | $3,646 |
| 2021 | 297 | 2 | 29 | $2,684 |
| 2020 | 243 | 2 | 26 | $3,632 |
| 2019 | 175 | 2 | 22 | $3,546 |
| 2018 | 187 | 1 | 25 | $4,932 |
See the largest Medicaid services in earlier years
2023
| Short return visit (20+ min) | 144 | $3,537 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy | 104 | $117 |
| TOBACCO NON-USER | 13 | $0 |
2022
| Short return visit (20+ min) | 149 | $3,395 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy | 177 | $251 |
2021
| Short return visit (20+ min) | 121 | $2,485 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy | 176 | $199 |
2020
| Short return visit (20+ min) | 141 | $3,496 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy | 102 | $137 |
2019
| Short return visit (20+ min) | 159 | $3,080 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 16 | $467 |
2018
| Short return visit (20+ min) | 187 | $4,932 |
Drugs they prescribed that Part D paid
$92,432
Pharmacies billed $92,432 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 2% of their Part D prescriptions (17 of 1,074) in 2024. At or below the middle of the specialty; the typical urology clinician is at 2%.
970 generic and 104 brand-name prescriptions · $92,432 in drug cost · 159 antibiotic prescriptions to 87 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Myrbetriq | 60 | $38,924 | $649 |
| Elmiron | 18 | $19,873 | $1,104 |
| Tamsulosin | 382 | $8,161 | $21 |
| Finasteride | 148 | $2,332 | $16 |
| Bethanechol Chloride | 21 | $2,310 | $110 |
See all 20 drugs
| Myrbetriq | 60 | $38,924 | $649 |
| Elmiron | 18 | $19,873 | $1,104 |
| Tamsulosin | 382 | $8,161 | $21 |
| Finasteride | 148 | $2,332 | $16 |
| Bethanechol Chloride | 21 | $2,310 | $110 |
| Desmopressin Acetate | 15 | $2,297 | $153 |
| Potassium Citrate Er | 14 | $2,277 | $163 |
| Dutasteride | 39 | $1,823 | $47 |
| Nitrofurantoin Mono-Macro | 31 | $1,505 | $49 |
| Bicalutamide | 35 | $1,084 | $31 |
| Testosterone Cypionate | 19 | $617 | $32 |
| Terazosin | 37 | $543 | $15 |
| Oxybutynin Chloride Er | 22 | $452 | $21 |
| Doxazosin Mesylate | 18 | $422 | $23 |
| Nitrofurantoin | 11 | $369 | $34 |
| Ciprofloxacin | 37 | $275 | $7 |
| Sulfamethoxazole-Trimethoprim | 35 | $209 | $6 |
| Levofloxacin | 33 | $122 | $4 |
| Imipramine | 11 | $98 | $9 |
| Tramadol | 14 | $16 | $1 |
Year by year
| 2024 | 1,074 | 285 | 2% (17) | 10% | $92,432 |
| 2023 | 1,368 | 325 | 2% (26) | None | $140,389 |
| 2022 | 1,453 | 363 | 2% (31) | None | $142,753 |
| 2021 | 1,444 | 340 | 3% (44) | None | $126,475 |
| 2020 | 1,283 | 308 | 3% (33) | 12% | $117,574 |
| 2019 | 1,167 | 302 | 3% (38) | 11% | $95,809 |
| 2018 | 1,291 | 299 | 3% (38) | 11% | $102,115 |
| 2017 | 2,170 | 494 | 2% (34) | None | $166,365 |
| 2016 | 2,991 | 602 | 3% (74) | None | $234,586 |
| 2015 | 2,712 | 512 | 3% (70) | None | $198,787 |
| 2014 | 2,340 | 429 | 4% (104) | None | $124,068 |
| 2013 | 1,470 | 294 | 6% (87) | None | $78,366 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 18 drugs
| Myrbetriq | 120 | $70,593 | $588 |
| Elmiron | 13 | $15,504 | $1,193 |
| Tamsulosin | 498 | $14,928 | $30 |
| Desmopressin Acetate | 25 | $6,893 | $276 |
| Finasteride | 201 | $4,649 | $23 |
| Bethanechol Chloride | 42 | $3,789 | $90 |
| Dutasteride | 23 | $2,102 | $91 |
| Bicalutamide | 40 | $2,095 | $52 |
| Nitrofurantoin Mono-Macro | 30 | $1,763 | $59 |
| Nitrofurantoin | 21 | $1,552 | $74 |
| Oxybutynin Chloride Er | 32 | $1,016 | $32 |
| Clotrimazole-Betamethasone | 14 | $653 | $47 |
| Terazosin | 32 | $637 | $20 |
| Testosterone Cypionate | 44 | $580 | $13 |
| Ciprofloxacin | 55 | $471 | $9 |
| Sulfamethoxazole-Trimethoprim | 23 | $397 | $17 |
| Levofloxacin | 16 | $161 | $10 |
| Tramadol | 16 | $53 | $3 |
2022: 23 drugs
| Myrbetriq | 115 | $63,940 | $556 |
| Elmiron | 19 | $25,352 | $1,334 |
| Tamsulosin | 485 | $15,722 | $32 |
| Bethanechol Chloride | 38 | $4,493 | $118 |
| Finasteride | 171 | $3,839 | $22 |
| Desmopressin Acetate | 28 | $3,201 | $114 |
| Nitrofurantoin Mono-Macro | 32 | $2,608 | $81 |
| Oxybutynin Chloride Er | 34 | $2,148 | $63 |
| Bicalutamide | 30 | $1,984 | $66 |
| Nitrofurantoin | 32 | $1,893 | $59 |
| Dutasteride | 28 | $1,330 | $48 |
| Testosterone Cypionate | 34 | $1,182 | $35 |
| Terazosin | 34 | $791 | $23 |
| Ciprofloxacin | 64 | $601 | $9 |
| Doxazosin Mesylate | 14 | $518 | $37 |
| Imipramine | 19 | $499 | $26 |
| Sulfamethoxazole-Trimethoprim | 50 | $481 | $10 |
| Levofloxacin | 29 | $417 | $14 |
| Clotrimazole-Betamethasone | 20 | $413 | $21 |
| Alfuzosin Hcl Er | 11 | $261 | $24 |
| Fluconazole | 15 | $101 | $7 |
| Hydrocodone-Acetaminophen | 19 | $93 | $5 |
| Tramadol | 12 | $34 | $3 |
2021: 23 drugs
| Myrbetriq | 71 | $48,143 | $678 |
| Elmiron | 20 | $22,753 | $1,138 |
| Tamsulosin | 486 | $10,560 | $22 |
| Bethanechol Chloride | 49 | $5,528 | $113 |
| Potassium Citrate Er | 13 | $4,297 | $331 |
| Oxybutynin Chloride Er | 66 | $4,237 | $64 |
| Desmopressin Acetate | 44 | $3,767 | $86 |
| Finasteride | 138 | $3,141 | $23 |
| Nitrofurantoin | 48 | $3,119 | $65 |
| Nitrofurantoin Mono-Macro | 40 | $2,843 | $71 |
| Bicalutamide | 25 | $1,330 | $53 |
| Testosterone Cypionate | 31 | $1,273 | $41 |
| Dutasteride | 23 | $1,005 | $44 |
| Terazosin | 52 | $811 | $16 |
| Ketoconazole | 16 | $608 | $38 |
| Doxazosin Mesylate | 19 | $565 | $30 |
| Ciprofloxacin | 64 | $407 | $6 |
| Sulfamethoxazole-Trimethoprim | 37 | $277 | $7 |
| Imipramine | 16 | $159 | $10 |
| Levofloxacin | 16 | $105 | $7 |
| Fluconazole | 18 | $97 | $5 |
| Hydrocodone-Acetaminophen | 26 | $90 | $3 |
| Tramadol | 18 | $28 | $2 |
2020: 18 drugs
| Myrbetriq | 69 | $43,806 | $635 |
| Elmiron | 12 | $21,083 | $1,757 |
| Tamsulosin | 399 | $8,482 | $21 |
| Bethanechol Chloride | 24 | $3,938 | $164 |
| Oxybutynin Chloride Er | 64 | $3,267 | $51 |
| Finasteride | 105 | $3,049 | $29 |
| Nitrofurantoin | 50 | $2,892 | $58 |
| Desmopressin Acetate | 51 | $2,753 | $54 |
| Nitrofurantoin Mono-Macro | 43 | $2,641 | $61 |
| Bicalutamide | 49 | $2,497 | $51 |
| Dutasteride | 34 | $1,667 | $49 |
| Terazosin | 51 | $962 | $19 |
| Doxazosin Mesylate | 18 | $618 | $34 |
| Testosterone Cypionate | 16 | $506 | $32 |
| Ciprofloxacin | 79 | $484 | $6 |
| Sulfamethoxazole-Trimethoprim | 46 | $231 | $5 |
| Hydrocodone-Acetaminophen | 28 | $107 | $4 |
| Levofloxacin | 17 | $69 | $4 |
2019: 19 drugs
| Myrbetriq | 50 | $27,636 | $553 |
| Elmiron | 14 | $15,625 | $1,116 |
| Tamsulosin | 345 | $7,468 | $22 |
| Oxybutynin Chloride Er | 78 | $4,838 | $62 |
| Bethanechol Chloride | 51 | $4,031 | $79 |
| Toviaz | 11 | $3,809 | $346 |
| Dutasteride | 25 | $2,679 | $107 |
| Finasteride | 104 | $2,501 | $24 |
| Nitrofurantoin | 30 | $1,967 | $66 |
| Bicalutamide | 38 | $1,404 | $37 |
| Desmopressin Acetate | 20 | $1,078 | $54 |
| Terazosin | 58 | $1,033 | $18 |
| Oxybutynin Chloride | 17 | $814 | $48 |
| Nitrofurantoin Mono-Macro | 21 | $717 | $34 |
| Ciprofloxacin | 71 | $631 | $9 |
| Clotrimazole-Betamethasone | 13 | $495 | $38 |
| Doxazosin Mesylate | 16 | $449 | $28 |
| Sulfamethoxazole-Trimethoprim | 45 | $410 | $9 |
| Hydrocodone-Acetaminophen | 34 | $175 | $5 |
2018: 18 drugs
| Myrbetriq | 50 | $21,770 | $435 |
| Elmiron | 13 | $12,952 | $996 |
| Tamsulosin | 421 | $11,656 | $28 |
| Bethanechol Chloride | 76 | $6,207 | $82 |
| Oxybutynin Chloride Er | 65 | $5,744 | $88 |
| Toviaz | 11 | $3,470 | $315 |
| Dutasteride | 23 | $2,989 | $130 |
| Finasteride | 133 | $2,726 | $20 |
| Nitrofurantoin | 32 | $2,584 | $81 |
| Nitrofurantoin Mono-Macro | 31 | $1,629 | $53 |
| Bicalutamide | 37 | $1,216 | $33 |
| Terazosin | 65 | $863 | $13 |
| Doxazosin Mesylate | 23 | $662 | $29 |
| Ciprofloxacin | 79 | $597 | $8 |
| Sulfamethoxazole-Trimethoprim | 55 | $378 | $7 |
| Hydrocodone-Acetaminophen | 29 | $167 | $6 |
| Levofloxacin | 12 | $94 | $8 |
| Fluconazole | 11 | $78 | $7 |
2017: 28 drugs
| Vesicare | 54 | $20,345 | $377 |
| Myrbetriq | 43 | $18,886 | $439 |
| Tamsulosin | 771 | $18,154 | $24 |
| Elmiron | 17 | $17,442 | $1,026 |
| Cialis | 14 | $7,748 | $553 |
| Oxybutynin Chloride Er | 97 | $6,850 | $71 |
| Toviaz | 14 | $6,321 | $452 |
| Bethanechol Chloride | 72 | $5,571 | $77 |
| Tolterodine Tartrate Er | 11 | $3,818 | $347 |
| Finasteride | 245 | $3,761 | $15 |
| Dutasteride-Tamsulosin | 23 | $3,620 | $157 |
| Oxybutynin Chloride | 59 | $2,573 | $44 |
| Nitrofurantoin | 51 | $2,504 | $49 |
| Nitrofurantoin Mono-Macro | 39 | $2,289 | $59 |
| Bicalutamide | 74 | $2,144 | $29 |
| Dutasteride | 37 | $2,114 | $57 |
| Potassium Citrate Er | 15 | $1,761 | $117 |
| Doxazosin Mesylate | 45 | $1,091 | $24 |
| Terazosin | 105 | $965 | $9 |
| Desmopressin Acetate | 17 | $727 | $43 |
| Ciprofloxacin | 87 | $645 | $7 |
| Sulfamethoxazole-Trimethoprim | 82 | $535 | $7 |
| Alfuzosin Hcl Er | 15 | $408 | $27 |
| Imipramine | 11 | $202 | $18 |
| Hydrocodone-Acetaminophen | 34 | $136 | $4 |
| Fluconazole | 14 | $77 | $5 |
| Levofloxacin | 11 | $64 | $6 |
| Hydrochlorothiazide | 18 | $38 | $2 |
2016: 29 drugs
| Vesicare | 78 | $23,266 | $298 |
| Tamsulosin | 1,004 | $22,791 | $23 |
| Elmiron | 20 | $22,423 | $1,121 |
| Myrbetriq | 30 | $16,308 | $544 |
| Oxytrol | 18 | $10,578 | $588 |
| Rapaflo | 26 | $9,402 | $362 |
| Tolterodine Tartrate Er | 32 | $7,335 | $229 |
| Oxybutynin Chloride Er | 106 | $6,291 | $59 |
| Toviaz | 15 | $5,906 | $394 |
| Bethanechol Chloride | 92 | $5,564 | $60 |
| Finasteride | 343 | $4,199 | $12 |
| Dutasteride-Tamsulosin | 26 | $3,996 | $154 |
| Oxybutynin Chloride | 110 | $3,480 | $32 |
| Nitrofurantoin Mono-Macro | 60 | $3,274 | $55 |
| Dutasteride | 52 | $3,238 | $62 |
| Potassium Citrate Er | 24 | $3,180 | $132 |
| Bicalutamide | 87 | $2,437 | $28 |
| Desmopressin Acetate | 60 | $1,906 | $32 |
| Nitrofurantoin | 44 | $1,654 | $38 |
| Ciprofloxacin | 179 | $1,439 | $8 |
| Sulfamethoxazole-Trimethoprim | 118 | $856 | $7 |
| Doxazosin Mesylate | 44 | $819 | $19 |
| Terazosin | 90 | $734 | $8 |
| Hydrocodone-Acetaminophen | 59 | $446 | $8 |
| Alfuzosin Hcl Er | 34 | $424 | $12 |
| Imipramine | 18 | $312 | $17 |
| Fluconazole | 21 | $165 | $8 |
| Levofloxacin | 22 | $158 | $7 |
| Hydrochlorothiazide | 11 | $60 | $5 |
2015: 27 drugs
| Tamsulosin | 899 | $25,083 | $28 |
| Avodart | 66 | $16,958 | $257 |
| Vesicare | 56 | $14,106 | $252 |
| Rapaflo | 53 | $12,216 | $230 |
| Jalyn | 46 | $8,657 | $188 |
| Tolterodine Tartrate Er | 42 | $8,269 | $197 |
| Myrbetriq | 23 | $7,259 | $316 |
| Bethanechol Chloride | 109 | $5,880 | $54 |
| Nitrofurantoin Mono-Macro | 111 | $5,795 | $52 |
| Premarin | 15 | $3,972 | $265 |
| Finasteride | 303 | $3,452 | $11 |
| Desmopressin Acetate | 59 | $3,155 | $53 |
| Oxybutynin Chloride | 97 | $2,957 | $30 |
| Potassium Citrate Er | 20 | $2,517 | $126 |
| Bicalutamide | 83 | $2,265 | $27 |
| Oxybutynin Chloride Er | 35 | $1,734 | $50 |
| Doxazosin Mesylate | 53 | $1,158 | $22 |
| Nitrofurantoin | 27 | $993 | $37 |
| Ciprofloxacin | 136 | $976 | $7 |
| Sulfamethoxazole-Trimethoprim | 95 | $678 | $7 |
| Terazosin | 91 | $562 | $6 |
| Hydrocodone-Acetaminophen | 51 | $381 | $7 |
| Alfuzosin Hcl Er | 33 | $363 | $11 |
| Levofloxacin | 12 | $219 | $18 |
| Imipramine | 13 | $179 | $14 |
| Fluconazole | 13 | $72 | $6 |
| Tramadol | 11 | $28 | $3 |
2014: 27 drugs
| Tamsulosin | 655 | $13,143 | $20 |
| Vesicare | 51 | $11,845 | $232 |
| Rapaflo | 54 | $9,861 | $183 |
| Avodart | 45 | $9,669 | $215 |
| Nitrofurantoin Mono-Macro | 151 | $8,067 | $53 |
| Tolterodine Tartrate Er | 42 | $7,519 | $179 |
| Elmiron | 12 | $6,822 | $569 |
| Jalyn | 32 | $5,118 | $160 |
| Bethanechol Chloride | 126 | $4,914 | $39 |
| Toviaz | 15 | $4,343 | $290 |
| Oxybutynin Chloride | 106 | $3,477 | $33 |
| Finasteride | 232 | $3,223 | $14 |
| Oxybutynin Chloride Er | 36 | $2,821 | $78 |
| Myrbetriq | 11 | $2,762 | $251 |
| Potassium Citrate Er | 15 | $2,377 | $158 |
| Desmopressin Acetate | 32 | $1,998 | $62 |
| Bicalutamide | 42 | $1,339 | $32 |
| Nitrofurantoin | 27 | $1,094 | $41 |
| Hydrocodone-Acetaminophen | 76 | $1,028 | $14 |
| Ciprofloxacin | 145 | $826 | $6 |
| Sulfamethoxazole-Trimethoprim | 122 | $773 | $6 |
| Doxazosin Mesylate | 33 | $629 | $19 |
| Terazosin | 62 | $434 | $7 |
| Alfuzosin Hcl Er | 13 | $260 | $20 |
| Imipramine | 13 | $195 | $15 |
| Trimethoprim | 11 | $131 | $12 |
| Tramadol | 13 | $49 | $4 |
2013: 20 drugs
| Avodart | 54 | $9,309 | $172 |
| Vesicare | 34 | $7,726 | $227 |
| Nitrofurantoin Mono-Macro | 127 | $7,310 | $58 |
| Tamsulosin | 367 | $7,106 | $19 |
| Rapaflo | 37 | $5,394 | $146 |
| Detrol La | 20 | $4,999 | $250 |
| Toviaz | 12 | $4,176 | $348 |
| Jalyn | 25 | $3,611 | $144 |
| Bethanechol Chloride | 66 | $2,643 | $40 |
| Finasteride | 97 | $2,364 | $24 |
| Desmopressin Acetate | 43 | $2,232 | $52 |
| Oxybutynin Chloride Er | 34 | $1,988 | $58 |
| Bicalutamide | 37 | $1,524 | $41 |
| Oxybutynin Chloride | 63 | $1,495 | $24 |
| Nitrofurantoin | 22 | $1,054 | $48 |
| Hydrocodone-Acetaminophen | 71 | $755 | $11 |
| Ciprofloxacin | 120 | $747 | $6 |
| Sulfamethoxazole-Trimethoprim | 61 | $456 | $7 |
| Imipramine | 18 | $340 | $19 |
| Terazosin | 22 | $245 | $11 |
Money from drug and device companies
$38 in 2025
| 2025 | 1 | 1 | None | $38 |
| 2024 | 1 | 1 | None | $22 |
| 2023 | 1 | 1 | None | $24 |
| 2022 | 1 | 2 | None | $42 |
| 2021 | 2 | 2 | None | $112 |
| 2019 | 3 | 5 | $5,000 | $5,872 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Boston Scientific | Rezum Generator | $38 | 1 payment
|
See the published payment
| Boston Scientific | Meals · 2025-08-02 | Rezum Generator | $38 |
See earlier years (2024, 2023, 2022, 2021, 2019)
2024: $22
| Urogen Pharma | Jelmyto | $22 | 1 payment
|
2023: $24
| Abbvie | Lupron Depot | $24 | 1 payment
|
2022: $42
| Rochester Medical | None | $42 | 2 payments
|
2021: $112
| Astellas Pharma US | None | $100 | 1 payment
|
| Urogen Pharma | Jelmyto | $12 | 1 payment
|
2019: $5,872
| Varian Medical Systems | None | $5,720 | 3 payments
|
| Boston Scientific | General Therapies | $122 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $31 | 1 payment
|
Professional record
- NPI
- 1821014820
- Licence
- CA A31900California A31900: Current · expires 2028-10-31
- Group
- United Urology Consultants, P.C. · First Choice Physician Partners · Emergency and Acute Care Medical Corporation · County of Santa Clara · Kaweah Delta Health Care District
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 1982938247
- Taxonomy
- Urology (208800000X)
- Mailing address
- 8851 Center Dr, #501, La Mesa, CA, 91942
- NPI first listed
- 2006-07-14
- NPI last updated
- 2015-03-13
This is when the NPI record was last certified, not a medical board exam.